Improvement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab

BACKGROUND: In order to help in selecting the optimum bone-modifying agent (BMA; zoledronic acid or denosumab), we investigated the impact of the BMA on the renal function of patients with bone metastases. MATERIALS AND METHODS: The present study consisted of 118 patients who were treated with denos...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamasaki, Mutsushi, Yuasa, Takeshi, Uehara, Sho, Fujii, Yasuhisa, Yamamoto, Shinya, Masuda, Hitoshi, Fukui, Iwao, Yonese, Junji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5124438/
https://www.ncbi.nlm.nih.gov/pubmed/27402103
http://dx.doi.org/10.1007/s10147-016-1019-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5124438/
https://www.ncbi.nlm.nih.gov/pubmed/27402103
http://dx.doi.org/10.1007/s10147-016-1019-4

Ejemplares similares